GO
Loading...

Enter multiple symbols separated by commas

Regeneron Pharmaceuticals Inc

More

  • Top 10 highest-paid CEOs Tuesday, 26 May 2015 | 6:00 AM ET

    1. David Zaslav, Discovery Communications, $156.1 million, up 368 percent. 2. Leslie Moonves, CBS, $54.4 million, down 17 percent. 3. Philippe Dauman, Viacom, $44.3 million, up 19 percent.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments. Sales of Eylea in the United States leapt 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handsomely beat the average analyst...

  • Early movers: BABA, PCLN, PG, COST, ANN & more Thursday, 7 May 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye injection Eylea to grow at a faster rate than it had previously forecast. Sales of Eylea in the United States jumped 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handily beat the average analyst estimate by 20 cents.

  • Regeneron profit rises as Eylea sales jump Thursday, 7 May 2015 | 6:39 AM ET

    May 5- Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea. The U.S. biotechnology company's net profit rose to $76 million, or 66 per share, in the first quarter ended March 31, from $68.3 million, or 61 cents per share, a year earlier. Revenue, including collaboration payments...

  • Rising bond yields could contain stocks Thursday, 7 May 2015 | 6:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    The rise in interest rates can affect stocks as traders wait for the job reports coming out on Friday.

  • Rising rates could contain stocks Wednesday, 6 May 2015 | 7:27 PM ET
    Traders work on the floor of the New York Stock Exchange.

    The rise in interest rates can affect stocks as traders wait for the job reports coming out on Friday.

  • What matters to markets this week Monday, 4 May 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • Jobs report is big but watch out for Europe Friday, 1 May 2015 | 7:21 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • 10 most outrageously priced stocks Wednesday, 22 Apr 2015 | 11:24 AM ET
    Traders work on the floor of the New York Stock Exchange.

    There are 10 stocks in the Standard & Poor's 500 that are trading for 100 times their diluted earnings, reports USAToday.

  • Cramer: The best places for you to put new money Monday, 30 Mar 2015 | 6:55 PM ET
    A Cofor worker wearing a safety hard hat moves drilling pipes near to a rig at the geothermal energy drilling site operated by Semhach SA in Villejuif, France.

    Jim Cramer reveals the top places to invest new money on the stock market.

  • Cramer: 4 horsemen of biotech & semis are back Sunday, 29 Mar 2015 | 1:33 PM ET
    A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange, July 18, 2014.

    Jim Cramer saw the proximate cause of this week's decline to these stocks. Now they're showing signs of life.

  • Cramer Remix: A bottom in biotech? Hardly Friday, 27 Mar 2015 | 7:23 PM ET
    Jim Cramer on Mad Money.

    “Mad Money” host Jim Cramer sees a pulse back in biotechs. Time to jump in?

  • Worst 5 stocks of the week. Here's how to trade them Friday, 27 Mar 2015 | 1:23 PM ET

    CNBC Pro highlights the worst-performing stocks this week and analyzes whether the negative momentum will continue.

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • Lightning Round: Problem with Visa's split Tuesday, 24 Mar 2015 | 7:33 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.